Haitang Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haitang Hu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Kaifu Kang
Department of Nephrology, the Affiliated Shunde First People's Hospital of Southern Medical University, Penglai Road, Daliang District, Foshan 528300, China
1 shared publication - Shu-Feng Zhou
Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL 33612, USA
1 shared publication - Wenfang Chen
Department of Pathology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China
1 shared publication - Xianrui Dou
Department of Nephrology, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde), Foshan, China
1 shared publication - Yongdong Liu
Department of Pathology, the First Affiliated Hospital of Sun Yat-sen University, 58# Zhongshan Road II, Guangzhou 510080, China
1 shared publication - Yongle Ju
Department of Nephrology, the Affiliated Shunde First People's Hospital of Southern Medical University, Penglai Road, Daliang District, Foshan 528300, China
1 shared publication
Latest Publications
- Open Access
- 13 October 2011
- Published by Springer Nature in Diagnostic Pathology
- Vol. 6 (1) , 99
Concurrent nephrotic syndrome and acute renal failure caused by chronic lymphocytic leukemia (CLL): a case report and literature review
Kidney injury associated with lymphocytic leukemia (CLL) is typically caused by direct tumor infiltration which occasionally results in acute renal failure. Glomerular involvement presenting as proteinuria or even nephrotic syndrome is exceptionally rare. Here we report a case of 54-year-old male CLL patient with nephrotic syndrome and renal failure. The lymph node biopsy confirmed that the patients had CLL with remarkable immunoglobulin light chain amyloid deposition. The renal biopsy demonstrated the concurrence of AL amyloidosis and neoplastic infiltration. Combined treatment of fludarabine, cyclophosphamide and rituximab resulted in remission of CLL, as well as the renal disfunction and nephrotic syndrome, without recurrence during a 12-month follow-up. To our knowledge, this is the first case of CLL patient showing the nephrotic syndrome and acute renal failure caused by AL amyloidosis and neoplastic infiltration. Though AL amyloidosis caused by plasma cell dyscrasia usually responses poorly to chemotherapy, this patient exhibited a satisfactory clinical outcome due to successful inhibition of the production of amylodogenic light chains by combined chemotherapy. Virtual Slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2479639195566762.
- 13 October 2011
- Published by Springer Nature in Diagnostic Pathology
- Vol. 6 (1) , 99
Open AccessConcurrent nephrotic syndrome and acute renal failure caused by chronic lymphocytic leukemia (CLL): a case report and literature review
Kidney injury associated with lymphocytic leukemia (CLL) is typically caused by direct tumor infiltration which occasionally results in acute renal failure. Glomerular involvement presenting as proteinuria or even nephrotic syndrome is exceptionally rare. Here we report a case of 54-year-old male CLL patient with nephrotic syndrome and renal failure. The lymph node biopsy confirmed that the patients had CLL with remarkable immunoglobulin light chain amyloid deposition. The renal biopsy demonstrated the concurrence of AL amyloidosis and neoplastic infiltration. Combined treatment of fludarabine, cyclophosphamide and rituximab resulted in remission of CLL, as well as the renal disfunction and nephrotic syndrome, without recurrence during a 12-month follow-up. To our knowledge, this is the first case of CLL patient showing the nephrotic syndrome and acute renal failure caused by AL amyloidosis and neoplastic infiltration. Though AL amyloidosis caused by plasma cell dyscrasia usually responses poorly to chemotherapy, this patient exhibited a satisfactory clinical outcome due to successful inhibition of the production of amylodogenic light chains by combined chemotherapy. Virtual Slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2479639195566762.